Macro Intelligence: ResMed's strong Q4 earnings propel shares to one-year high
ResMed shares surge to a one-year high following impressive 4Q earnings and a 10% dividend increase. With analysts rating the stock a "BUY", CEO Mick Farrell views the impact of weight loss drugs as a growth opportunity.
![Video poster image](https://cf-images.eu-west-1.prod.boltdns.net/v1/static/2830693144001/1da6e9f8-d714-4c4e-b2ea-37c87060abd8/d879b2a1-d99c-4bc0-ad06-3b5a181f6652/1280x720/match/image.jpg)
Article written by Juliette Saly (ausbiz)
Deep dive into ResMed
ResMed (NYSE: RMD), (ASX: RMD) beat market expectations with its Q4 numbers.
Revenue in the quarter increased by 9% to US$1.2 billion. On a constant currency basis, revenue rose 10%.
ResMed quarterly financial results comparison
![](http://a.c-dn.net/c/content/dam/ResMedPL.PNG/jcr:content/renditions/original-size.webp)
Income from operations increased 38%, while earnings per share came in at US$1.98. The Q4 dividend was increased by 10% to US$0.53. Over the year, ResMed reported an 11% increase in revenue to US$4.7 billion.
ResMed key financial metrics summary
![](http://a.c-dn.net/c/content/dam/image28YkzmGYDrFUMedit.png/jcr:content/renditions/original-size.webp)
Breathing new life
Mask sales saw a significant 15% increase compared to last year, driven by successful resupply programs and strong demand for the new AirFit F40 mask. This new mask is a direct competitor to Fisher & Paykel Healthcare’s smallest and lightest mask, the Nova Micro.
The result was well received by the market, with ResMed hitting a one-year high on the ASX after its earnings, despite the global market sell-off.
Impressive share performance
Technical data from ASX TradeMatch shows ResMed is in a long-term bullish pattern, with the 5-day moving average of the stock price above the 50-day moving average and the 200-day moving average trending higher.
Shares in both Australia and the US have risen close to 75% over the past five years. They’re up 30% since the lows of 2023 when ResMed was hit by short-sellers worried the take-up of GLP-1 drugs to control weight would lessen demand for its sleep apnoea devices, after trials from the drugmakers Eli Lilly and Novo Nordisk showed they reduced obstructive sleep apnoea.
ResMed daily chart
![](http://a.c-dn.net/c/content/dam/ResMedIncASX)_20240806_15.52.png/jcr:content/renditions/original-size.webp)
The elephant in the room
Addressing the so-called “elephant in the room”, ResMed CEO Mick Farrell told ausbiz he sees the threat posed by weight loss drugs as an opportunity.
Farrell said a ResMed study of more than 800,000 patients who used weight loss drugs found they were 10.7% more likely to turn to a ResMed or equivalent therapy because more patients were being brought into the system. “They’re not a headwind, they’re a tailwind,” Farrell told ausbiz.
Capturing new patients
“And the question is for ResMed, how well can we capture all these new patients that are on GLP-1 drugs and telling their GP ‘I think I have a sleep and breathing problem’?” Meanwhile, Roger Montgomery from Montgomery Investment Management exercised a degree of caution over the data, saying “It sounds a little like the manufacturer of black t-shirts saying black t-shirts cure cancer…. The findings are promising but they lack statistical rigour.”
Is ResMed a Buy?
On Monday, 5 August, when equity markets sold off across the globe on recession fears, ASX-listed shares of ResMed were the best performer on the market, rising as much as 7% to A$34.02 intraday, their highest level in a year.
Analysts' reactions
Analysts are scrambling to rerate ResMed after its Q4 results, with both the US and Australian listed shares rated a “BUY”.
JP Morgan has lifted its price target on the medical equipment maker to A$37 from A$34.50. The broker sees 20% EPS growth for ResMed as strong mask sales, rising prices, and operating efficiencies continue.
Strong growth projections
Macquarie lists the stock as Outperform and raised its target price to A$36.25 from A$35.40. Analysts at Macquarie say strong growth in mask sales highlights the "strength of the installed base," and expect existing patients to represent around 80% of total mask and accessories revenue.
Ord Minnett has kept its rating at Accumulate but increased its target price to A$35.40 from A$33 due to ResMed's 3% increase in EPS forecasts for FY25 and FY26.
Meanwhile, Citi raised its price target on the stock by 13% to A$34 and Wilsons increased its target by 12% to A$40.25.
ResMed analyst ratings
![](http://a.c-dn.net/c/content/dam/MeanRMD8YkzmGYDrFUMedit.PNG/jcr:content/renditions/original-size.webp)
Consensus on ResMed
The average recommendation on ResMed is a BUY with an average price target of A$36.58, according to Refinitiv data. That’s a near 12% upside from Monday’s closing price and suggests current long-term growth of 13.44%.
When it comes to NYSE-listed shares, analysts also have a BUY recommendation with an average price target of US$224.46.
ResMed analyst ratings and price target trends
![](http://a.c-dn.net/c/content/dam/RMDmeanNYSE8YkzmGYDrFUMedit.PNG/jcr:content/renditions/original-size.webp)
IGA, may distribute information/research produced by its respective foreign affiliates within the IG Group of companies pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the research is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, IGA accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact IGA at 6390 5118 for matters arising from, or in connection with the information distributed.
The information/research herein is prepared by IG Asia Pte Ltd (IGA) and its foreign affiliated companies (collectively known as the IG Group) and is intended for general circulation only. It does not take into account the specific investment objectives, financial situation, or particular needs of any particular person. You should take into account your specific investment objectives, financial situation, and particular needs before making a commitment to trade, including seeking advice from an independent financial adviser regarding the suitability of the investment, under a separate engagement, as you deem fit.
No representation or warranty is given as to the accuracy or completeness of this information. Consequently, any person acting on it does so entirely at their own risk. Please see important Research Disclaimer.
Please also note that the information does not contain a record of our trading prices, or an offer of, or solicitation for, a transaction in any financial instrument. Any views and opinions expressed may be changed without an update.
![](http://a.c-dn.net/c/content/dam/publicsites/igcom/uk/images/Rebrand/Article_banners/Shares-global-component-banner.jpg/jcr:content/renditions/original-size.webp)
Explore the markets with our free course
Discover and learn how the range of markets you can trade on with IG Academy's online course – ‘Introducing the financial markets’.
Put learning into action
Try out what you’ve learned in this shares strategy article risk-free in your demo account.
Ready to trade shares?
Put the lessons in this article to use in a live account – upgrading is quick and easy.
- Trade on over 10,000 popular global stocks
- Protect your capital with risk management tools
- React to breaking news with out-of-hours trading on 70 key US stocks
Inspired to trade?
Put your new knowledge into practice. Log in to your account now.
Live prices on most popular markets
- Forex
- Shares
- Indices
See more forex live prices
See more shares live prices
Prices above are subject to our website terms and agreements. Prices are indicative only. All shares prices are delayed by at least 15 mins.
See more indices live prices
Prices above are subject to our website terms and agreements. Prices are indicative only. All shares prices are delayed by at least 20 mins.